New cancer clinical trial: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Published on: October 30, 2018 at 12:00PM
Condition:   Breast Cancer
Interventions:   Biological: Pembrolizumab (K);   Drug: Placebo (P);   Drug: Paclitaxel (X);   Drug: Doxorubicin hydrochloride (A);   Drug: Epirubicin (E);   Drug: Cyclophosphamide (C);   Drug: Endocrine therapy;   Radiation: Radiation therapy;   Procedure: Surgery
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting
https://ift.tt/2Q8FkVi